Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Level Biotechnology's share price for the quarter that ended in Dec. 2025 was NT$33. Level Biotechnology's Shares Outstanding (EOP) for the quarter that ended in Dec. 2025 was 32.5 Mil. Therefore, Level Biotechnology's market cap for the quarter that ended in Dec. 2025 was NT$1,070.9 Mil.
Level Biotechnology's quarterly market cap
increased
from Jun. 2025 (NT$1,053.1 Mil) to Sep. 2025 (NT$1,088.8 Mil) but then
declined
from Sep. 2025 (NT$1,088.8 Mil) to Dec. 2025 (NT$1,070.9 Mil).
Level Biotechnology's annual market cap
increased
from Dec. 2023 (NT$988.2 Mil) to Dec. 2024 (NT$1,038.5 Mil) and
increased
from Dec. 2024 (NT$1,038.5 Mil) to Dec. 2025 (NT$1,070.9 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Level Biotechnology's Enterprise Value for Today is NT$828.0 Mil.
Level Biotechnology (ROCO:3118) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Level Biotechnology Market Cap Related Terms
Level Biotechnology Market Cap Historical Data
* Premium members only.
The historical data trend for Level Biotechnology's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:3118 vs VRTX, REGN, ALNY: Market Cap Comparison
For the Biotechnology subindustry, Level Biotechnology's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Level Biotechnology Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Level Biotechnology's Market Cap distribution charts can be found below:
* The bar in red indicates where Level Biotechnology's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Level Biotechnology's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Level Biotechnology (ROCO:3118) has a Market Cap of NT$1,030.4 Mil as of Jul. 21, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Level Biotechnology and its competitors. According to the industry distribution chart, Level Biotechnology ranks #997 out of 1423 companies in the Biotechnology industry, placing it in the top 70.1%.
Is Level Biotechnology's Market Cap too high?
Level Biotechnology's current Market Cap is NT$1,030.4 Mil. Based on the distribution chart, Level Biotechnology ranks #997 out of 1423 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Level Biotechnology has a GF Score™ of 76/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Level Biotechnology's Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Level Biotechnology ranks #997 out of 1423 companies for Market Cap. This places Level Biotechnology in the lower half of its industry. The industry median Market Cap is 111.61. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 111.61, based on 1,423 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Level Biotechnology and its competitors. For the Biotechnology industry, the median Market Cap is 111.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Level Biotechnology's current Market Cap is NT$1,030.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Level Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, Level Biotechnology (ROCO:3118) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$35.57, compared to a current price of NT$31.75 — trading 10.7% below its estimated fair value. The current Market Cap is NT$1,030.4 Mil. Level Biotechnology's overall GF Score™ is 76/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Level Biotechnology (ROCO:3118), the current Market Cap is NT$1,030.4 Mil as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Level Biotechnology (ROCO:3118) Overvalued in 2026?
Based on GuruFocus' analysis, Level Biotechnology stock appears to be undervalued.
The current stock price of NT$31.75 is trading 10.7% below its estimated GF Value™ of NT$35.57.
GuruFocus considers Level Biotechnology to be Modestly Undervalued.
Key valuation signals for ROCO:3118:
Market Cap: NT$1,030.4 Mil
GF Value™: NT$35.57 vs. price of NT$31.75 (10.7% below fair value)
No single metric tells the full story. See the ROCO:3118 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Level Biotechnology Inc is a Taiwan-based company engaged in the sales of biomedical products and providing preclinical testing services. The company has three reportable segments: Department A and B, Department C, and Department D. Department A and Department B sell the cell culture consumables and the antibody reagents, Department C sells the instruments and equipment, and Department D provides CRO services. The majority of revenue is derived from the Department A and B.
76GF Score
Get the complete analysis for ROCO:3118
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:3118 has been successfully added to your 
